Peringatan Keamanan

Oral LD50s are 350 to 400 mg betaxolol/kg in mice and 860 to 980 mg/kg in rats. Predicted symptoms of overdose include bradycardia, congestive heart failure, hypotension, bronchospasm, and hypoglycemia.

Betaxolol

DB00195

small molecule approved investigational

Deskripsi

A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

Struktur Molekul 2D

Berat 307.4278
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 14-22 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Absorption of an oral dose is complete. There is a small and consistent first-pass effect resulting in an absolute bioavailability of 89% ± 5% that is unaffected by the concomitant ingestion of food or alcohol.

Metabolisme

Primarily hepatic. Approximately 15% of the dose administered is excreted as unchanged drug, the remainder being metabolites whose contribution to the clinical effect is negligible.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. No food interactions are expected.

Interaksi Obat

1453 Data
Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Betaxolol is combined with Duloxetine.
Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Betaxolol is combined with Levodopa.
Risperidone Betaxolol may increase the hypotensive activities of Risperidone.
Ceritinib Betaxolol may increase the bradycardic activities of Ceritinib.
Ivabradine Betaxolol may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Betaxolol.
Deferasirox The serum concentration of Betaxolol can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Betaxolol can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Betaxolol can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Betaxolol can be decreased when it is combined with Teriflunomide.
Alfuzosin Alfuzosin may increase the hypotensive activities of Betaxolol.
Amifostine Betaxolol may increase the hypotensive activities of Amifostine.
Diazoxide Diazoxide may increase the hypotensive activities of Betaxolol.
Methylphenidate Methylphenidate may decrease the antihypertensive activities of Betaxolol.
Dexmethylphenidate Dexmethylphenidate may decrease the antihypertensive activities of Betaxolol.
Obinutuzumab Betaxolol may increase the hypotensive activities of Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the hypotensive activities of Betaxolol.
Rituximab Betaxolol may increase the hypotensive activities of Rituximab.
Desmopressin Desmopressin may decrease the antihypertensive activities of Betaxolol.
Doxapram Doxapram may decrease the antihypertensive activities of Betaxolol.
Sumatriptan Sumatriptan may decrease the antihypertensive activities of Betaxolol.
Phenmetrazine Phenmetrazine may decrease the antihypertensive activities of Betaxolol.
Naratriptan Naratriptan may decrease the antihypertensive activities of Betaxolol.
Rizatriptan Rizatriptan may decrease the antihypertensive activities of Betaxolol.
Dopamine Dopamine may decrease the antihypertensive activities of Betaxolol.
Dutasteride Dutasteride may decrease the antihypertensive activities of Betaxolol.
Finasteride Finasteride may decrease the antihypertensive activities of Betaxolol.
Yohimbine Yohimbine may decrease the antihypertensive activities of Betaxolol.
Epicaptopril Epicaptopril may decrease the antihypertensive activities of Betaxolol.
1-benzylimidazole 1-benzylimidazole may decrease the antihypertensive activities of Betaxolol.
Amineptine Amineptine may decrease the antihypertensive activities of Betaxolol.
Flibanserin Flibanserin may decrease the antihypertensive activities of Betaxolol.
Naluzotan Naluzotan may decrease the antihypertensive activities of Betaxolol.
Nitrous oxide Nitrous oxide may decrease the antihypertensive activities of Betaxolol.
Cinitapride Cinitapride may decrease the antihypertensive activities of Betaxolol.
Tyramine Tyramine may decrease the antihypertensive activities of Betaxolol.
Ifenprodil Ifenprodil may decrease the antihypertensive activities of Betaxolol.
Dimetacrine Dimetacrine may decrease the antihypertensive activities of Betaxolol.
Moxisylyte Moxisylyte may decrease the antihypertensive activities of Betaxolol.
Tianeptine Tianeptine may decrease the antihypertensive activities of Betaxolol.
Oxaprotiline Oxaprotiline may decrease the antihypertensive activities of Betaxolol.
Atipamezole Atipamezole may decrease the antihypertensive activities of Betaxolol.
Tetrahydrocannabivarin Tetrahydrocannabivarin may decrease the antihypertensive activities of Betaxolol.
Piclozotan Piclozotan may decrease the antihypertensive activities of Betaxolol.
Siponimod Siponimod may decrease the antihypertensive activities of Betaxolol.
Idazoxan Idazoxan may decrease the antihypertensive activities of Betaxolol.
Tramazoline Tramazoline may decrease the antihypertensive activities of Betaxolol.
Amitriptylinoxide Amitriptylinoxide may decrease the antihypertensive activities of Betaxolol.
Dibenzepin Dibenzepin may decrease the antihypertensive activities of Betaxolol.
Quinupramine Quinupramine may decrease the antihypertensive activities of Betaxolol.
Trichloroethylene Trichloroethylene may decrease the antihypertensive activities of Betaxolol.
Fenozolone Fenozolone may decrease the antihypertensive activities of Betaxolol.
Melitracen Melitracen may decrease the antihypertensive activities of Betaxolol.
Lofepramine Lofepramine may decrease the antihypertensive activities of Betaxolol.
Xenon Xenon may decrease the antihypertensive activities of Betaxolol.
Iprindole Iprindole may decrease the antihypertensive activities of Betaxolol.
Buflomedil Buflomedil may decrease the antihypertensive activities of Betaxolol.
Diethyl ether Diethyl ether may decrease the antihypertensive activities of Betaxolol.
Imipramine oxide Imipramine oxide may decrease the antihypertensive activities of Betaxolol.
Mefenorex Mefenorex may decrease the antihypertensive activities of Betaxolol.
5-methoxy-N,N-dimethyltryptamine 5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Betaxolol.
Quinoline Yellow WS Quinoline Yellow WS may decrease the antihypertensive activities of Betaxolol.
Solriamfetol Solriamfetol may decrease the antihypertensive activities of Betaxolol.
Sufentanil Sufentanil may decrease the antihypertensive activities of Betaxolol.
Remifentanil Remifentanil may decrease the antihypertensive activities of Betaxolol.
Halothane Halothane may decrease the antihypertensive activities of Betaxolol.
Opipramol Opipramol may decrease the antihypertensive activities of Betaxolol.
Selpercatinib Selpercatinib may decrease the antihypertensive activities of Betaxolol.
Naxitamab Naxitamab may decrease the antihypertensive activities of Betaxolol.
Cannabidiol The metabolism of Betaxolol can be decreased when combined with Cannabidiol.
Atomoxetine Atomoxetine may decrease the antihypertensive activities of Betaxolol.
Protriptyline Protriptyline may decrease the antihypertensive activities of Betaxolol.
Isoflurane Isoflurane may decrease the antihypertensive activities of Betaxolol.
Propofol Propofol may decrease the antihypertensive activities of Betaxolol.
Desflurane Desflurane may decrease the antihypertensive activities of Betaxolol.
Sevoflurane Sevoflurane may decrease the antihypertensive activities of Betaxolol.
Solifenacin Solifenacin may decrease the antihypertensive activities of Betaxolol.
Lurasidone Lurasidone may decrease the antihypertensive activities of Betaxolol.
Butriptyline Butriptyline may decrease the antihypertensive activities of Betaxolol.
Amiodarone The therapeutic efficacy of Betaxolol can be increased when used in combination with Amiodarone.
Bupivacaine The serum concentration of Bupivacaine can be increased when it is combined with Betaxolol.
Dipyridamole Dipyridamole may increase the bradycardic activities of Betaxolol.
Disopyramide Disopyramide may increase the bradycardic activities of Betaxolol.
Dronedarone Dronedarone may increase the bradycardic activities of Betaxolol.
Fingolimod Betaxolol may increase the bradycardic activities of Fingolimod.
Floctafenine The risk or severity of adverse effects can be increased when Betaxolol is combined with Floctafenine.
Mepivacaine The serum concentration of Mepivacaine can be increased when it is combined with Betaxolol.
Methacholine Betaxolol may increase the bronchoconstrictory activities of Methacholine.
Midodrine The therapeutic efficacy of Midodrine can be decreased when used in combination with Betaxolol.
Nifedipine The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Betaxolol.
Propafenone The risk or severity of adverse effects can be increased when Propafenone is combined with Betaxolol.
Regorafenib Regorafenib may increase the bradycardic activities of Betaxolol.
Reserpine Reserpine may increase the hypotensive activities of Betaxolol.
Deserpidine Deserpidine may increase the hypotensive activities of Betaxolol.
Guanethidine Guanethidine may increase the hypotensive activities of Betaxolol.
Rivastigmine Betaxolol may increase the bradycardic activities of Rivastigmine.
Mirabegron The serum concentration of Betaxolol can be increased when it is combined with Mirabegron.
Abiraterone The serum concentration of Betaxolol can be increased when it is combined with Abiraterone.
Nicorandil Nicorandil may increase the hypotensive activities of Betaxolol.
Molsidomine Molsidomine may increase the hypotensive activities of Betaxolol.

Target Protein

Beta-1 adrenergic receptor ADRB1
Beta-2 adrenergic receptor ADRB2

Referensi & Sumber

Synthesis reference: Ramesh Joshi, Muthukrishnan Murugan, Dinesh Garud, Sanjay Borikar, Mukund Gurjar, "PROCESS FOR PREPARATION OF S-(-)-BETAXOLOL AND SALTS THEREOF." U.S. Patent US20060004109, issued January 05, 2006.
Artikel (PubMed)
  • PMID: 20418154
    Canotilho J, Castro RA: The structure of betaxolol studied by infrared spectroscopy and natural bond orbital theory. Spectrochim Acta A Mol Biomol Spectrosc. 2010 Aug;76(3-4):395-400. doi: 10.1016/j.saa.2010.03.038. Epub 2010 Apr 4.

Contoh Produk & Brand

Produk: 24 • International brands: 1
Produk
  • Betaxolol
    Tablet, film coated • 10 mg/1 • Oral • US • Generic • Approved
  • Betaxolol
    Tablet, film coated • 10 mg/1 • Oral • US • Generic • Approved
  • Betaxolol
    Tablet, film coated • 20 mg/1 • Oral • US • Generic • Approved
  • Betaxolol
    Solution / drops • 5 mg/1mL • Ophthalmic • US • Generic • Approved
  • Betaxolol
    Tablet, film coated • 10 mg/1 • Oral • US • Generic • Approved
  • Betaxolol
    Tablet, film coated • 20 mg/1 • Oral • US • Generic • Approved
  • Betaxolol
    Tablet, film coated • 10 mg/1 • Oral • US • Generic • Approved
  • Betaxolol
    Tablet, film coated • 20 mg/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 24 produk.
International Brands
  • Betaxon

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul